Tirzepatide in Mounjaro Cuts Alcohol Intake Over 50%, Study Shows
In a groundbreaking finding for those exploring the broader impacts of GLP-1 and GIP receptor agonists, tirzepatide—the active ingredient in Mounjaro—significantly reduces alcohol consumption and prevents relapse-like behavior in animal models. Published in the journal eBioMedicine, this University of Gothenburg study highlights how tirzepatide blunts the brain's reward system, specifically targeting dopamine levels in the lateral septum. Voluntary alcohol intake dropped by more than half, while binge-drinking episodes were drastically curtailed, offering new insights into potential treatments for alcohol use disorder (AUD).
The Study: Key Findings on Tirzepatide and Alcohol Consumption
Alcohol use disorder remains a major public health challenge, affecting millions worldwide with limited effective pharmacological options. The study, titled "Tirzepatide reduces alcohol drinking and relapse-like behaviours in rodents," conducted by researchers at the University of Gothenburg in collaboration with the Medical University of South Carolina, used a multifaceted approach to evaluate tirzepatide's effects.
Behavioral and Intake Paradigms
Researchers employed several established rodent models to assess alcohol-related behaviors:
- Intermittent access two-bottle choice: Mimics voluntary drinking patterns.
- Drinking in the dark: Models binge-like drinking.
- Alcohol deprivation effect: Tests relapse-like behavior after abstinence.
Results were striking: tirzepatide dose-dependently reduced voluntary alcohol consumption (P < 0.001), prevented binge drinking (P < 0.01), and blocked relapse-like drinking (P < 0.001). Even after repeated administration, efficacy was maintained (P < 0.001). Both male and female animals showed clear reductions in long-term consumption.
Molecular and Neurotransmitter Insights
Tirzepatide attenuated alcohol-induced dopamine release in the nucleus accumbens (P < 0.001), diminishing the rewarding properties of alcohol. This was measured via locomotor activity, conditioned place preference, and microdialysis. In the lateral septum—a brain region critical for motivation, reward, and relapse—the drug induced sustained synaptic depression (P < 0.05) and altered histone regulatory proteins (P < 0.05), which influence gene expression linked to addiction.
"We observed clear and robust reductions in long-term alcohol consumption, binge-like drinking, and relapse-like drinking in both male and female animals. What makes this study particularly compelling is that it also provides new insight into how this class of drugs may influence the brain's reward system," says Christian Edvardsson, a doctoral student in pharmacology at the Sahlgrenska Academy, University of Gothenburg.
These changes do not prove causation for reduced drinking but suggest they are part of tirzepatide's biological mechanisms. The study also noted metabolic effects, including reduced body weight (P < 0.001), adipose tissue mass (P < 0.01), hepatic triglycerides (P < 0.01), and pro-inflammatory cytokines (P < 0.05), aligning with tirzepatide's known profile.
How Tirzepatide Works: Targeting the Gut-Brain Axis and Reward Pathways
Tirzepatide is the first dual agonist for GLP-1 (glucagon-like peptide-1) and GIP (glucose-dependent insulinotropic polypeptide) receptors, hormones central to the gut-brain axis. Approved for type 2 diabetes and widely used off-label for weight loss as Mounjaro, it mimics satiety signals to regulate appetite and glucose.
In the context of alcohol consumption, tirzepatide modulates the mesolimbic reward circuitry. Alcohol typically spikes dopamine in reward centers like the nucleus accumbens, creating the addictive "buzz." Tirzepatide mutes this by:
- Reducing dopamine release triggered by alcohol.
- Acting on the lateral septum to dampen motivation for relapse.
- Potentially altering epigenetic factors via histone proteins.
This mechanism provides a neurobiological explanation for anecdotal reports and prior observations of reduced alcohol craving among patients on GLP-1/GIP therapies.
Comparison to Semaglutide: Building on Prior GLP-1 Research
The University of Gothenburg team previously showed that semaglutide—the active ingredient in Ozempic and Wegovy—reduces alcohol consumption in rats. Tirzepatide builds on this by offering dual agonism, potentially enhancing efficacy. While semaglutide targets GLP-1 receptors alone, tirzepatide's GIP component may broaden its impact on reward and metabolic pathways, as evidenced by stronger reductions in binge and relapse behaviors here.
